ArticleDiabetologia2026
Adipocyte-derived exosomal ANGPTL2 promotes beta cell dysfunction via the EIF2α/ATF4/CHOP stress pathway in mice.
Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aims/hypothesisObesity-associated lipotoxicity drives beta cell failure in type 2 diabetes, but the adipose-to-islet signals that promote beta cell dysfunction remain incompletely defined. We hypothesised that angiopoietin-like protein 2 (ANGPTL2) carried by lipotoxic adipocyte-derived exosomes contributes to adipose-to-islet signalling that impairs beta cell function.
methodsExosomes from palmitate- or PBS-treated 3T3-L1 adipocytes were applied to MIN6 cells and primary mouse islets to assess beta cell function and identity. In vivo, mice underwent adipose-specific Angptl2 knockdown under high-fat diet (HFD) feeding, followed by metabolic phenotyping and assessment of beta cell function. Adipose-derived exosomes from HFD-fed mice with or without adipose Angptl2 knockdown were injected into normal-chow-fed recipient mice, and endocrine marker composition and islet secretory function were evaluated. Mechanistic studies in MIN6 cells used co-immunoprecipitation, pharmacological rescue experiments and Eif2α (also known as Eif2s1) knockdown to interrogate stress signalling.
resultsExosomes derived from palmitate-treated adipocytes were efficiently internalised by beta cells and resulted in impaired insulin content and secretion, accompanied by reduced beta cell identity markers and induction of dedifferentiation signatures. ANGPTL2 was enriched in lipotoxic adipocyte-derived exosomes and accumulated in beta cells in an exosome-dependent manner. Angptl2 silencing in adipocytes lowered exosomal ANGPTL2 and mitigated islet dysfunction in vitro. In vivo, adipose-specific Angptl2 knockdown reduced islet ANGPTL2 without changing islet Angptl2 mRNA and improved glucose tolerance, with the AUC of the IPGTT decreasing from 2300.2 ± 165.5 to 1583.7 ± 88.8 mmol/l × min (mean ± SD). In adipose-exosome transfer experiments, recipients of HFD-short hairpin (sh)Angptl2-exosome (Exo) showed lower islet ANGPTL2 abundance and improved ex vivo islet glucose-stimulated insulin secretion (GSIS), with stimulated insulin secretion increasing from 6.0 ± 0.3% (mean ± SD) in the HFD-sh-negative control (NC)-Exo group to 10.9 ± 0.6% in the HFD-shAngptl2-Exo group. Mechanistically, ANGPTL2 associated with eukaryotic translation initiation factor 2α (EIF2α) and increased protein kinase R-like endoplasmic reticulum kinase (PERK)-associated EIF2α by approximately 2.8-fold, whereas this difference was lost after further normalisation to input EIF2α, supporting a substrate-availability model. PERK inhibition and integrated stress response inhibitor both attenuated ANGPTL2-induced activating transcription factor-4 (ATF4)/C/EBP homologous protein (CHOP) signalling and improved GSIS. CONCLUSIONS/
interpretationLipotoxic adipocyte-derived exosomes increase ANGPTL2 abundance in recipient beta cells and contribute to beta cell dysfunction and identity disruption by amplifying PERK-dependent EIF2α/ATF4/CHOP signalling. Adipose ANGPTL2 and circulating exosome-associated ANGPTL2 represent candidate targets and biomarkers for preserving beta cell function in obesity-associated dysglycaemia.
Indexed as
Identifiers
42829353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.